
Neumic Therapeutics Ltd
New Zealand · Biotech & life sciences · Undetermined

ZymoChem
United States · Biotech & life sciences · Series A
Compatibility /100
65/100
High potentialWhy talk
- Same sector (Biotech & life sciences): peer learning on regulation, pricing and investors; Neumic Therapeutics Ltd works on University therapeutics spin-off (presumed neuroscience), ZymoChem on Synthetic biology – bio-based materials.
- Stage not comparable (Undetermined / Series A).
- Neumic Therapeutics Ltd likely needs funding — ZymoChem (United States, Series A, $25M raised) can offer investor introductions (inferred from public profile).
Score anatomy
Each segment is what one dimension adds, out of 100.
Score by goal
Dimension by dimension
Needs ↔ offers
5.0 / 10 pts
ZymoChem can help Neumic Therapeutics Ltd.
- Neumic Therapeutics Ltd likely needs funding — ZymoChem (United States, Series A, $25M raised) can offer investor introductions (inferred from public profile).
Market bridge
2.5 / 10 pts
Distant markets.
- ZymoChem is based in United States (North America): a landing pad on another continent, both ways.
Customer potential
0.0 / 5 pts
Neither side has a product on the market yet.
No supporting signal in the records.
Sector synergy
50.0 / 50 pts
Same sector: peers.
- Same sector (Biotech & life sciences): peer learning on regulation, pricing and investors; Neumic Therapeutics Ltd works on University therapeutics spin-off (presumed neuroscience), ZymoChem on Synthetic biology – bio-based materials.
Stage complementarity
7.5 / 25 pts
Weak stage signal.
- Stage not comparable (Undetermined / Series A).
How the score works
Each dimension gives a value between 0 and 1, multiplied by its weight; the compatibility is the sum (0–100). Weights for “Peers”: Needs ↔ offers 10, Market bridge 10, Customer potential 5, Sector synergy 50, Stage complementarity 25. Declared needs and offers count fully; when a startup has declared nothing, a few needs/offers are inferred from its public profile (for example, no known traction ⇒ needs customers) and count at half value.
Potential blends compatibility (65%) with the mean global score of both startups (35%): 59/100 — high from 50, medium from 36.